Our study showedthat the use of sitagliptin was associated with an increased risk of HHF in patientswith T2DM receiving dialysis, especially in those without ACE inhibitors treatment.Longer duration and prospective studies are needed to prove these findings andeffects. Here, ACE is linked to type 2 diabetes mellitus.